Wealth Enhancement Advisory Services’s Sarepta Therapeutics SRPT Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.04M	Sell	55,009 -34,462	-39%	-$652K	﹤0.01%	2041
2026 Q1	$1.82M	Sell	89,471 -17,288	-16%	-$335K	﹤0.01%	1442
2025 Q4	$2.41M	Buy	106,759 +62,981	+144%	+$1.33M	﹤0.01%	1414
2025 Q3	$1.01M	Buy	+43,778	New	+$780K	﹤0.01%	1857
2025 Q2	–	Sell	-4,365	Closed	-$279K	–	3480
2025 Q1	$279K	Sell	4,365 -334	-7%	-$35.2K	﹤0.01%	2512
2024 Q4	$571K	Buy	4,699 +218	+5%	+$26.7K	﹤0.01%	1894
2024 Q3	$560K	Sell	4,481 -500	-10%	-$69.1K	﹤0.01%	1754
2024 Q2	$787K	Sell	4,981 -15	-0.3%	-$1.93K	﹤0.01%	1388
2024 Q1	$647K	Buy	4,996 +2,504	+100%	+$307K	﹤0.01%	1447
2023 Q4	$240K	Sell	2,492 -253	-9%	-$24.3K	﹤0.01%	1987
2023 Q3	$333K	Buy	+2,745	New	+$310K	﹤0.01%	1678

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Wealth Enhancement Advisory Services's SRPT Position: Q2 2026 in Review

Wealth Enhancement Advisory Services reduced its Sarepta Therapeutics (SRPT) stake by 39% in Q2 2026, selling an estimated $652K and leaving 55,009 shares worth $1.04M. The position accounts for ﹤0.01% of the portfolio, ranked #2041.

Wealth Enhancement Advisory Services first reported a position in SRPT in Q3 2023 and has held it in 11 quarters since. The position peaked at $2.41M in Q4 2025. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

Wealth Enhancement Advisory Services held 55,009 shares of Sarepta Therapeutics worth $1.04M as of Q2 2026.
Wealth Enhancement Advisory Services sold 34,462 Sarepta Therapeutics shares in Q2 2026, an estimated $652K.
Sarepta Therapeutics made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #2041 holding.
Wealth Enhancement Advisory Services first reported a position in Sarepta Therapeutics in Q3 2023 and has held it in 11 quarters since.
Wealth Enhancement Advisory Services's Sarepta Therapeutics position peaked at $2.41M in Q4 2025.
323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.